Previous 10 | Next 10 |
All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter’s transformation, responded to treatment (Objective Response Rate of 100%) GLPG5201 showed an acceptable safety profile with no cytokine release syndrome (CRS) higher than gr...
Galapagos ( NASDAQ: GLPG ) stock fell ~8% on Thursday after filgotinib failed to meet the main goals as induction therapy in a phase 3 trial in patients with moderate to severe Crohn's disease (CD) and the company decided to not to file for European approval of the drug. Filgotini...
The two induction cohorts missed the co-primary endpoints of clinical remission and endoscopic response at Week 10 In the maintenance phase, filgotinib 200mg once daily achieved the co-primary endpoints of clinical remission and endoscopic response at Week 58 The safety findings were gene...
Summary Galapagos is a Belgiu- based commercial biotech, led by ex-J&J CSO Paul Stoffels. The company holds ~$4Bn cash and currently trading at a negative $1.8Bn enterprise value. 2023 has various clinical catalysts coupled with a potential large-scale M&A, which we believe ...
Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...
Summary GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing. They have a huge cash stockpile. I haven’t covered Galapagos ( GLPG ) in a while. My last coverage of t...
Galapagos ( NASDAQ: GLPG ) announced Dr. Walid Abi-Saab has decided to retire from the company as Chief Medical Officer and member of the executive committee, effective 31 December 2022. He will stay with the company until 31 May 2023 to ensure a smooth transition. ...
Summary David Einhorn's 13F stock portfolio value increased from $1.29B to $1.41B this quarter. Greenlight increased Kyndryl Holdings, LivaNova PLC, and Southwestern Energy while dropping Chemours, International Seaways, and Warner Bros. Discovery. The largest three positions are at...
He highlighted the TYK2 inhibitor GLPG3667 for lupus as having some viability. While the company is set to begin phase 2 trials by the end of the year, Leone sees indications in lupus and dermatomyositis as minor opportunities. See why Seeking Alpha contributor Bram de Haas is bullish...
Galapagos press release ( NASDAQ: GLPG ): 9M GAAP EPS of -€0.16. Revenue of €410.2M (+29.0% Y/Y). Clear path forward for accelerated growth and value creation Reshape innovation model and build fit-for-purpose organization in key strategic ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...